Tenax Therapeutics (TENX) EV to EBITDA (2010 - 2026)

Tenax Therapeutics has disclosed EV to EBITDA across 16 years of filings, most recently posting 28.75 for Q2 2026.

• In Q2 2026, EV to EBITDA fell 176.82% year-over-year to 28.75; the TTM figure through Jun 2026 stood at 7.87 (down 125.23% YoY), while the FY2025 annual figure was 6.75, down 41318.86% from the prior year.
• EV to EBITDA came in at 28.75 for Q2 2026 at Tenax Therapeutics, up from 36.47 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 599.75 in Q1 2022 to a low of 215.38 in Q1 2023.
• Average EV to EBITDA over 5 years is 79.8, with a median of 0.64 recorded in 2023.
• Year-over-year, EV to EBITDA jumped 527.12% in 2022 and sank 52974.27% in 2025.
• Over 5 years, EV to EBITDA stood at 101.46 in 2022, then slumped by 99.68% to 0.33 in 2023, then slumped by 86.73% to 0.04 in 2024, then slumped by 52974.27% to 23.13 in 2025, then declined by 24.29% to 28.75 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 28.75 in Q2 2026, 36.47 in Q1 2026, and 23.13 in Q4 2025.